Innocare (09969.HK) announced that the National Medical Products Administration Drug Evaluation Center has accepted and prioritized the biologics license application for Tafasitamab in combination with Lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma in adult patients who are not eligible for autologous stem cell transplantation. Tafasitamab is a humanized cell lysis immunotherapy targeting CD19 with optimized Fc domain.
諾誠健華(09969.HK)免疫療法Tafasitamab生物製品許可申請獲受理
Innocare (09969.HK) immunotherapy Tafasitamab biological product license application accepted.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.